EcoDrugPlus

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSSMAG00000003010
Gene Symbol: HTR2CL1
1 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSSMAG00000010887
Gene Symbol: HTR5AB
3 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSMAG00000009051
Gene Symbol: HTR1B
3 Cross references
182 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSSMAG00000032913
Gene Symbol: HTR3A
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSSMAG00000030425
Gene Symbol: HTR4
2 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 7-Like

Ensembl ID : ENSSMAG00000037769
Gene Symbol: LOC118283839
2 Cross references
196 Possible Orthologues:

60s Ribosomal Protein L19-Like

Ensembl ID : ENSSMAG00000020107
Gene Symbol: LOC118287533
2 Cross references
317 Possible Orthologues:

60s Ribosomal Protein L5

Ensembl ID : ENSSMAG00000003009
Gene Symbol: LOC118317684
3 Cross references
455 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSMAG00000012640
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSSMAG00000028876
Gene Symbol: ADAM17
1 Cross references
210 Possible Orthologues:

Adam Metallopeptidase Domain 17a

Ensembl ID : ENSSMAG00000020548
Gene Symbol: ADAM17A
3 Cross references
208 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSSMAG00000005793
Gene Symbol: ADAMTS5
1 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).